Tampa, Fla. (July 21, 2005) - Nanobac Life Sciences, Inc. (OTCBB: NNBP) (“Nanobac” or “the Company”) announced today key research findings about the characterization and structure of Nanobacteria. The Company also announced new business initiatives that will leverage Nanobac’s growing intellectual property estate to take advantage of diagnostic and therapeutic opportunities.
Since 1988 researchers at Nanobac Life Sciences, Inc. have been studying a pathogen that they believe is responsible for numerous chronic diseases affecting humankind. They called this pathogen Nanobacteria because of its small size, roughly 100 billionths of a meter, and because of its ability to replicate or propagate. Nanobacteria have also been characterized as calcifying nano-particles (CNPs) because of their ability to create calcium phosphate coated vesicles or shells around themselves. These bony like particles ultimately accumulate and become calcified plaques. However, until now, very little has been known about this mineralizing pathogen and its role in human disease.
At a recent meeting of representatives from the biopharmaceutical industry, Dr. Olavi Kajander, Nanobac’s Chief Science Officer, presented data for the first time showing the structure and pathogenic characteristics of Nanobacteria or CNPs. The data was presented at the 2005 PDA Viral and TSE Safety Conference, on May 16-18, 2005, in Bethesda, MD. At this meeting, Dr. Kajander disclosed that Nanobacteria, or CNPs, actually consist of a core phospholipid vesicle, surrounded by a calcium phosphate layer that binds proteins from its surroundings. These proteins involve blood clotting proteins, inflammation promoters and regulators and many other proteins that are implicated in many diseases.
“Nanobacteria or calcified nano-particles are like ticking time bombs,” stated Dr. Kajander. “The particles carry many of the known proteins implicated in coronary artery disease and many other diseases associated with pathological calcification or plaque. Therefore, the particles are capable of activating multiple disease pathways. This leads us to believe that many diseases such as kidney stones, atherosclerosis, prostatitis, arthritis and psoriasis are local manifestations of a systemic disease,” Dr. Kajander concluded.
The Company’s new business initiatives will be introduced to take advantage of market opportunities emanating from it’s research discoveries and growing intellectual property portfolio.
Nanobac’s drug discovery and development efforts are focused on applying new and existing compounds that effectively inhibit, destroy or neutralize the particles. Nanobacteria or CNPs offer a unique model for studying many diseases involving soft tissue calcification or plaque. We have developed drug screening assays using this model to screen compounds using proprietary in vitro screening assays. Compounds showing efficacy can quickly move into animal models. Our business strategy is to develop, license and commercialize compounds to address the unmet needs of patients within the cardiovascular and urological disease markets. While the Company's primary focus remains cardiovascular and urological diseases, Nanobac researchers are investigating compounds for a wide range of other therapeutic areas.
Dietary supplement products can reach the consumer market much quicker than a new pharmaceutical product. These products use ingredients such as, vitamins, minerals, herbs, or amino acids that are “Generally Regarded as Safe” (GRAS). At Nanobac Life Sciences, we apply the same approach that we use to test new pharmaceutical compounds, to testing dietary supplement ingredients and formulations. Ingredients and formulations that demonstrate the desired effects can be formulated into products and then validated in clinical trials. The Company markets dietary supplements through its dietary supplement marketing arm, Nanobac Sciences, LLC. Nanobac Sciences currently markets a combination Oral Supplement and EDTA rectal suppository sold under the Nanobac Supplements brand.
Nanobac Oy is a wholly owned subsidiary of Nanobac Life Sciences. Nanobac Oy Diagnostics division operates out of our Nanobac Oy facility in Kuopio, Finland. Our diagnostics division markets both in vitro diagnostic products and laboratory services.
Nanobac Oy diagnostics division manufactures and markets IVD kits and reagents for the detection of Nanobacteria or calcifying nano-particles. Products include our NanoCapture™ and Nano-Sero™ ELISA assays and our Nano-Vision™ line of primary monoclonal antibodies and immunohistochemical reagents. These products are marketed through a network of distributors.
Nanobac Oy Clinical Laboratory provides specialized clinical laboratory testing services to clinicians, hospitals, and laboratories. We specialize in providing advanced technologies for the detection of Nanobacteria or CNPs in human samples. Nanobac Oy Clinical Laboratory is fully accredited by the Social Health Ministry of Finland.
Nanobacteria or CNPs expose a risk for biopharmaceuticals containing human or animal blood components or blood and animal tissue derived raw materials or production substrates.
Nanobac BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating Nanobacteria or CNPs from raw materials or production substrates. Our contamination control program focuses on host cell lines, animal and human derived materials, raw materials, availability of diagnostic procedures and downstream processes capable of inactivating or removing contaminants.
Nanobac Life Sciences, Inc. is dedicated to improving people’s health through the detection and eradication of Calcifying Nano-Particles, also referred to as “Nanobacteria”. The Company’s pioneering research is establishing the pathogenic role of Nanobacteria in soft tissue calcification, particularly in coronary artery heart disease, prostatitis and vascular disease.
Nanobac has identified and established two biomarkers of nanobacterial infection, and expects to file for FDA approval of its NB2(TM) ELISA assays to detect nanobacteria antigen and IgG antibody. It is also leveraging its proprietary knowledge and intellectual property to develop novel therapeutics to treat nano-particle infections. The Company currently markets a patented nanobiotic regimen and has developed tests to detect Nanobacteria in blood, serum, tissues, urine and spinal fluids. Nanobac Life Sciences, Inc. is headquartered in Tampa, Florida. For more information, please visit our websites at: http://www.nanobaclifesciences.com or http://www.nanobacsciences.com.
Investors are cautioned that certain statements contained in this document as well as some statements in periodic press releases and some oral statements of Nanobac Life Sciences, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Life Sciences, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Life Sciences, Inc. has no specific intention to update these statements.